1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

Pfizer banks on King Pharma's new painkillers

  1. Balzafire
    WASHINGTON -- Pfizer's purchase of King Pharmaceuticals announced Tuesday represents a $3.6 billion investment in an emerging class of painkillers that are designed to be less addictive than older pills such as OxyContin. The new products have been touted by federal health officials as an important way to curb prescription drug abuse, but they are relatively untested in the marketplace.

    In recent years, King, based in Bristol, Tenn., has thrown the bulk of its research funding into the effort to develop abuse-resistant versions of morphine and other opioid-based drugs. The effort has been encouraged by regulators at the Food and Drug Administration, who have watched reports of abuse climb into the millions over the last decade. Patients will often crush or dissolve extended-release painkillers to get an especially euphoric high.

    Last summer, King's drug Embeda became the first tamper-resistant medication to win approval from the FDA. The morphine tablet contains an extra ingredient, naltrexone, which neutralizes the effect of the morphine if it is crushed or chewed.

    But analysts have been disappointed by the drug's sales -- just $15 million in the last quarter -- and raised questions about the commercial potential of two other pain medications in King's pipeline: Remoxy and Acurox.

    While Embeda aims at the morphine market, the main ingredient in Remoxy and Acurox is oxycodone. Both have been designed to make them less vulnerable to drug abuse. Remoxy is a version of extended-release oxycodone, but the opiate is contained in a thick liquid form. Acurox is intended to be a fast-acting form of the drug. If it is exposed to alcohol or water, the oxycodone inside gets trapped in a gel mixture that is hard to draw into a needle. If the drug is snorted, it creates a burning, irritating sensation in the nose.

    Oxycodone has a larger share of the pain drug market than morphine, so Remoxy and Acurox should have much higher sales than Embeda, said Gary Nachman, an analyst at Susquehanna & Co.

    Purdue Pharma's branded version of the drug, Oxycontin, was the top-selling painkiller in the U.S. last year, with total sales of over $3 billion. Purdue recently launched its own abuse-resistant version of the drug.

    "With Pfizer promoting it, there's no reason Remoxy couldn't get to $500 million, and I'm sure Pfizer is thinking it could be even more than that," Nachman said.

    Sales of tamper-proof medications also have been tempered by the limited claims allowed by FDA regulators. Current labeling and advertising for the drugs does very little to differentiate them from older products. The FDA, which approves all claims for prescription drugs, has pointed out that no company has conducted a long-term study showing that the products actually reduce addiction, overdose and death over time.

    "FDA has been blatantly clear that companies won't get this claim until they figure out what types of studies need to be done to show these are less abusable," Nachman said. "The FDA is going to be very careful about how they represent these products."

    Studies conducted by King on Embeda showed that when it was crushed or chewed, it was less pleasurable than traditional morphine. However, the drug's label notes that the feature has not been proven to reduce abuse. The FDA has delayed approval of Remoxy and Acurox, partly because it wants more proof they really will cut down on abuse. The agency will hold a public meeting next week to discuss study designs for demonstrating the benefits of tamper-resistant painkillers.

    King previously said it would refile for approval of Remoxy in the fourth quarter of 2010 and Acurox in the first quarter of 2011.

    Associated Press
    October 17, 2010


  1. dyingtomorrow
    I wonder if they are "anal proof" too.

    That would make a great news article -

    "Anal Abuse of Prescription Medication Skyrockets"

    'anal abuse' - can I coin that term?
  2. Code9
    I'm going to go ahead and assume that they've patented this formula and are spinning the abuse-proof line as a way to get doctors to favor it over the non-abuse-proof pills.

    I'm sure that they do not really believe it to be abuse-proof . After all, they're a large company of chemists that put the pill together. And if it can be put together, it can be taken apart.

    Its surprising that the FDA is the voice of reason here:
    They should be applauded for not using the nebulous term "abuse" and for using real, quantitative terms: addiction, overdose and death.
To make a comment simply sign up and become a member!